EUVIMEDEUVIMED entdecken
Crossref

Dupilumab in Children with Atopic Dermatitis and History of Liver Transplantation: Two Case Studies

Nikolay N. Murashkin, Ekaterina S. Bulokhova, Olga E. Panova, Leonid A. Opryatin, Roman V. Epishev, Anastasiya Yu. Ufimtseva, Roman A. Ivanov, Mariya A. Leonova, Daniil L. Sokolov

Current Pediatrics · 14.11.2026 · 25 (5) · 478-485

DOI: 10.15690/vsp.v25i5.3113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Pediatrics, online erschienen am 14.11.2026. Verfasst von Nikolay N. Murashkin und 8 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD), primarily diagnosed in children after orthotopic liver transplantation, is considered as potential transplant-acquired allergy (TAA) developed de novo due to long-term immunosuppressive therapy. The options for systemic AD therapy in this population are significantly limited as administration of cyclosporine A, methotrexate, systemic glucocorticoids, and Janus kinase inhibitors is associated with hepatotoxicity, potentiation of overall immunosuppression, and risk of latent viral infections reactivation. Dupilumab, monoclonal antibody to IL-4 receptor α-subunit, represents pathogenetically justified option due to selective blockade of Th2 signaling pathway while maintaining Th1-mediated immune response. Case reports. Observations of two male patients aged 5 and 8 years with severe AD are presented. AD manifested 3–4 years after orthotopic liver transplantation performed in infancy for extrahepatic biliary atresia and congenital hepatic fibrosis. Reduction of skin lesions and itching severity, preservation of transplant function, and absence of any side effects were noted during the follow-up period.

Conclusion

These observations demonstrate clinical efficacy and favorable safety profile of dupilumab in the management of severe AD in children with history of orthotopic liver transplantation (including those with concomitant chronic HBV infection) and confirm feasibility of its implementation in multidisciplinary management and regular monitoring of transplant function.

Zitieren

APA

Murashkin, N. N., Bulokhova, E. S., Panova, O. E., Opryatin, L. A., Epishev, R. V., Ufimtseva, A. Y., Ivanov, R. A., Leonova, M. A., & Sokolov, D. L. (2026). Dupilumab in Children with Atopic Dermatitis and History of Liver Transplantation: Two Case Studies. Current Pediatrics, 25(5), 478-485. https://doi.org/10.15690/vsp.v25i5.3113

Vancouver

Murashkin NN, Bulokhova ES, Panova OE, Opryatin LA, Epishev RV, Ufimtseva AY, et al. Dupilumab in Children with Atopic Dermatitis and History of Liver Transplantation: Two Case Studies. Current Pediatrics. 2026;25(5):478-485. doi:10.15690/vsp.v25i5.3113

BibTeX
@article{Murashkin2026,
  author = {Murashkin, Nikolay N. and Bulokhova, Ekaterina S. and Panova, Olga E. and Opryatin, Leonid A. and Epishev, Roman V. and Ufimtseva, Anastasiya Yu. and Ivanov, Roman A. and Leonova, Mariya A. and Sokolov, Daniil L.},
  title = {Dupilumab in Children with Atopic Dermatitis and History of Liver Transplantation: Two Case Studies},
  journal = {Current Pediatrics},
  year = {2026},
  volume = {25},
  number = {5},
  pages = {478--485},
  doi = {10.15690/vsp.v25i5.3113}
}
Kostenlos starten →